Takara Bio Of Japan To Jointly Develop Liver Cancer Therapy With Chinese University
This article was originally published in PharmAsia News
Executive Summary
Takara Bio announced Sept. 1 the company will jointly develop a liver cancer therapy with Zhongshan University Cancer Center in Guangzhou, China. Takara will combine its own immunotherapy with Zhongshan University's radio frequency therapy to kill cancer cells. The two parties plan to conduct the research on 30 patients in two years. According to Takara, immunotherapy combined with radio frequency therapy could lead to prevention of cancer recurrence. (Click here for more - Japanese language